Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322972
Status:
COMPLETED
Last Update Posted:
2015-09-09
First Post:
2006-05-05
Brief Title:
Trachoma Amelioration in Northern Amhara TANA
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Eliminating Trachoma With Repeat Mass Drug Treatment
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TANA
Brief Summary:
The WHO has initiated a program to eliminate trachoma blinding eye infection caused by Chlamydia trachomatis in large part by mass distributions of oral azithromycin The proposed study will determine the frequency and treatment target of community-wide mass antibiotic treatment We will also study the impact of mass antibiotic distribution on antibiotic-resistance in pneumococcus
Detailed Description:
The proposed study is a group-randomized trial to determine the frequency and treatment target of community-wide mass antibiotic treatment to eliminate trachoma We will also study the impact of community-wide antibiotic distribution on antibiotic-resistance in pneumococcus Communities in Goncha Siso Enese district of East Gojam Zone Ethiopia will be randomly assigned to different treatment schemes and monitored to study the following research questions
Specific Aim 1 To determine whether biannual mass treatments is more likely to eliminate ocular chlamydia from hyper-endemic communities than annual mass treatments
Specific Aim 2 To determine whether children form a core group for the transmission of trachoma
Specific Aim 3 To determine whether latrine construction prevents the return of infection into a community after mass treatment
Specific Aim 4 To determine the effect of mass azithromycin treatments on antibiotic resistance in pneumococcus and the reduction in mortality
Specific Aim 5 To determine whether annual mass treatments are more likely to eliminate ocular chlamydia from hyper-endemic communities than biennial mass treatments
Specific Aim 1 To determine whether biannual mass treatments is more likely to eliminate ocular chlamydia from hyper-endemic communities than annual mass treatments
Specific Aim 2 To determine whether children form a core group for the transmission of trachoma
Specific Aim 3 To determine whether latrine construction prevents the return of infection into a community after mass treatment
Specific Aim 4 To determine the effect of mass azithromycin treatments on antibiotic resistance in pneumococcus and the reduction in mortality
Specific Aim 5 To determine whether annual mass treatments are more likely to eliminate ocular chlamydia from hyper-endemic communities than biennial mass treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None